What is the Difference Between Tecfidera and Vumerity?

Tecfidera and Vumerity are both medications used to treat multiple sclerosis (MS), specifically relapsing forms of the disease. They have the same active metabolite, monomethyl fumarate (MMF), which means they have the same therapeutic effect in people with MS. However, there are some differences between the two drugs:

• Chemical structure: Vumerity contains diroximel fumarate, while Tecfidera contains dimethyl fumarate.
• Side effects: Vumerity is better tolerated than Tecfidera and causes fewer gastrointestinal (GI) adverse events. As a result, fewer people stop taking Vumerity due to GI side effects compared to Tecfidera.

Both Vumerity and Tecfidera are administered in the same way, through delayed-release capsules. Despite their differences in chemical structure and side effect profiles, both drugs are effective in treating MS and have been approved by the FDA for this purpose.

Comparative Table: Tecfidera vs Vumerity

Vumerity (diroximel fumarate) and Tecfidera (dimethyl fumarate) are both medications used to treat multiple sclerosis (MS). Here is a table comparing their differences:

Both Vumerity and Tecfidera have the same active metabolite, monomethyl fumarate (MMF), which is responsible for their therapeutic effect in treating MS. However, Vumerity is associated with less severe gastrointestinal side effects compared to Tecfidera. The two medications are administered in the same way (as delayed-release capsules) and used to treat the same condition (MS).